Medicis Aims to Alter Bioequivalence Requirements for Generic Solodyn

Drug Industry Daily
A A
The waiver provisions in the FDA’s draft guidance of bioequivalence requirements for generic versions of Medicis Pharmaceutical’s once-daily, oral acne drug would put the public at risk, the company argues in a citizen petition.

To View This Article:

Login

Subscribe To Drug Industry Daily